• Industry: Life Sciences
  • Type: White paper
  • Date: 4/25/2012

Risk and Disclosure in the Global Pharmaceutical Industry 

KPMG's analysis of recent financial filings shows the continuing drive to improve shareholder value through innovative therapies in the face of the ongoing price pressures, the patent cliff, and regulatory requirements.

Pricing, patent-related risks and generic competition dominate disclosure tables. Political instability, natural disasters, and the risk posed by use of information technology show the greatest increase in disclosure. There was a 13 percent increase in the total number of risks disclosed by the companies we reviewed.


Share this

Share this